Bio Protocol’s native token $BIO It rose significantly today. The gathering was fueled by renewed hype about the project’s push into AI-powered decentralized science (DeSci). A recent feature on Bankless and a viral X post from the page itself highlighted breakthrough advances in AI-driven peptide drug discovery, which increased purchase pressure, according to a post on social media platform X.
AI agent designs ADHD peptide in 24 hours for less than $1,500
Bio Protocol’s CEO reveals that their team used AI to create a new ADHD drug candidate in just 24 hours. The company’s AI system, PeptAI, not only designed the drug, but tested it through various simulations and flagged real-world problems. Additionally, they estimated that the initial lab test would cost only $500 to $600.
Bio was featured on @Bankless about how AI is rewriting DeSci equations. Our peptide drug discovery AI agent, @peptai_, designed a novel peptide for ADHD in 24 hours. Wet lab validation of the peptide was completed for less than $1,500. Pharmaceutical companies arrive at the same decision point after millions of efforts… pic.twitter.com/WLLWqr05KU
— BioProtocol (@BioProtocol) April 23, 2026
Full early validation can cost approximately $1,000 to $1,500. Typically, pharmaceutical companies spend millions of dollars on research and it takes years to reach this stage.
How will AI change drug discovery?
This incident is a great example of how AI is transforming not only the traditional financial industry but also the research industry. Previously, it was known that the biggest barrier was funding. Because research moves forward only when it aligns with commercial interests, many important ideas could be left unexplored. DeSci (Decentralized Science) tried to solve this problem with community funding, but high discovery costs held it back. Today, AI is significantly reducing these costs.
DeSci and the community’s financial strength
If costs are low, even the DAO’s treasury can fund drug candidates until actual laboratory data is available. This opens the door to research into diseases typically ignored by pharmaceutical companies. For example, ADHD research on the orexin system has existed for years, but has never been commercially pursued until now. Bioprotocols are at the center of this change because they provide a platform that combines community funding with “pharmaceutical science” where AI systems act like researchers. Its tools, such as BIOS, are useful for research and analysis, and the platform routes funds to specialized research DAOs.
Challenges that still exist
Although great progress has been made, three major hurdles remain. First, key drug data is locked within pharmaceutical companies. Projects like Molecule aim to build open research hubs to solve this. Second, laboratory tests are still necessary and time-consuming. Third, human clinical trials remain expensive and follow traditional systems.
Strong buys indicate real interest
$BIO‘s recent price surge was no coincidence, but rather backed by extensive trading activity. Trading volume surged 146% to about $180 million, and prices rose about 10%. This type of move usually indicates strong buyer confidence, not just a short-term rally. A healthy turnover ratio of 2.64 also indicates that there is sufficient liquidity, meaning that large trades are possible without large price movements. What is even more noticeable is $BIO It moved independently of the broader crypto market and Bitcoin. While the entire virtual currency market is slowing down, $BIO continued to increase. This suggests strong project-specific demand, likely from large investors betting on the DeSci trend. At the time of writing, the price is $BIO According to CoinGecko, the token is valued at $0.0317, up 7.0% in the past 24 hours.
Key levels to focus on
For now, $BIO The $0.03 level should be held as support. If it falls below that, profit taking could cause the token price to fall towards $0.028. Meanwhile, the next target for the token is $0.035. A breakout of this level on heavy volume could easily lead to a rally towards $0.04. Also read: TRON TRX price falls despite bullish Treasury and consolidation news
